Comparison of subcutaneous low-molecular-weight heparin with intravenous standard heparin in proximal deep-vein thrombosis.

No abstract is available for this paper.

• Publication year

  1992

• Venue

  The Lancet

• Publication date

  1992-02-22

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/0140-6736(92)91054-CPMID 1346817
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Low molecular weight heparin

  2014cited by this paper
• Dose adjusted heparin treatment of deep venous thrombosis: a comparison of unfractionated and low molecular weight heparin

  2004cited by this paper
• Contrast Venography, the Gold Standard for the Diagnosis of Deep-Vein Thrombosis: lmprovement in Observer Agreement

  1992cited by this paper
• Ventilation-Perfusion Lung Scanning and the Diagnosis of Pulmonary Embolism: Improvement of Observer Agreement by the Use of a Lung Segment Reference Chart

  1992cited by this paper
• Prevention of deep vein thrombosis after elective hip surgery. A randomized trial comparing low molecular weight heparin with standard unfractionated heparin.

  1991cited by this paper
• A Randomised Trial of Subcutaneous Low Molecular Weight Heparin (CY 216) Compared with lntravenous Unfractionated Heparin in the Treatment of Deep Vein Thrombosis

  1991cited by this paper
• Failure of Computerized Impedance Plethysmography in the Diagnostic Management of Patients with Clinically Suspected Deep-Vein Thrombosis

  1991cited by this paper
• A New Computerized Impedance Plethysmograph: Accuracy in the Detection of Proximal Deep-Vein Thrombosis in Symptomatic Outpatients

  1991cited by this paper
• Drug therapy : heparin

  1991cited by this paper
• Diagnosis of deep-vein thrombosis using an objective Doppler method.

  1990cited by this paper
• From unfractionated heparins to low molecular weight heparins.

  1990cited by this paper
• Two Daily Subcutaneous Injections of Fragmin as Compared with Intravenous Standard Heparin in the Treatment of Deep Venous Thrombosis (DVT)

  1990cited by this paper
• Diagnosis of deep-vein thrombosis using an objective Doppler method.

  1990cited by this paper
• Heparin for 5 days as compared with 10 days in the initial treatment of proximal venous thrombosis.

  1990cited by this paper
• Treatment of acute venous thromboembolism with low molecular weight heparin (fragmin)

  1990cited by this paper
• Detection of deep-vein thrombosis by real-time B-mode ultrasonography.

  1989cited by this paper
• Unfractionated Heparin and CY 216: Pharmacokinetics and Bioavailabilities of the Antifactor Xa and IIa Effects after lntravenous and Subcutaneous Injection in the Rabbit

  1989cited by this paper
• Treatment of acute venous thromboembolism with low molecular weight heparin (Fragmin). Results of a double-blind randomized study.

  1989cited by this paper
• Overview of the Management of Thrombotic Disorders

  1989cited by this paper
• The Antithrombotic Activity and Pharmacokinetics of Enoxaparine, A Low Molecular Weight Heparin, In Humans Given Single Subcutaneous Doses of 20 to 80 mg

  1988cited by this paper
• Treatment of venous thromboembolism.

  1986cited by this paper
• Low-Molecular-Weight Heparin

  1986cited by this paper
• Safety and efficacy of warfarin started early after submassive venous thrombosis or pulmonary embolism.

  1986cited by this paper
• Continuous intravenous heparin compared with intermittent subcutaneous heparin in the initial treatment of proximal-vein thrombosis.

  1986cited by this paper
• Subcutaneous heparin treatment of deep venous thrombosis: a comparison of unfractionated and low molecular weight heparin.

  1986cited by this paper
• Low-molecular-weight heparin: is small beautiful?

  1986cited by this paper
• The Diagnosis of Acute, Recurrent, Deep‐vein Thrombosis: A Diagnostic Challenge

  1983cited by this paper
• The antithrombotic effects of warfarin and heparin following infusions of tissue thromboplastin in rabbits: clinical implications.

  1979cited by this paper
• A Table of Exact Confidence Limits for Differences and Ratios of Two Proportions and Their Odds Ratios

  1977cited by this paper
• Quantitative venographic assessment of deep vein thrombosis in the evaluation of streptokinase and heparin therapy.

  1977cited by this paper
• Venous thrombosis in the lower limbs: Its relation to pulmonary embolism

  1937cited by this paper

• 2026 AHA/ACC/ACCP/ACEP/CHEST/SCAI/SHM/SIR/SVM/SVN Guideline for the Evaluation and Management of Acute Pulmonary Embolism in Adults: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines.

  2026cites this paper
• Bleeding Events and Correlation with Anti-Xa Levels and Therapeutic Nadroparin Dose in Patients with Impaired Renal Function

  2025cites this paper
• A systematic review on anti-Xa monitoring in the therapeutic use of Low-Molecular-Weight Heparins.

  2025cites this paper
• Heparin: Over 100 Years of Anticoagulation.

  2025cites this paper
• To Compare the Effectiveness of Low-Molecular-Weight Heparin and Unfractionated Heparin in Reducing Lower Limb Girth in Deep Vein Thrombosis

  2024cites this paper
• Coagulation factor X promotes resistance to androgen-deprivation therapy in prostate cancer.

  2024cites this paper
• Synthesis of bioengineered heparin chemically and biologically similar to porcine-derived products and convertible to low MW heparin

  2024cites this paper
• Extended Pharmacologic Prophylaxis for Venous Thromboembolism After Colon Cancer Surgery Is Associated With Improved Long-term Survival

  2024cites this paper
• The Tumorigenicity of Breast Cancer Cells Is Reduced upon Treatment with Small Extracellular Vesicles Isolated from Heparin Treated Cell Cultures

  2023cites this paper
• Anti-Factor Xa Level Monitoring for Enoxaparin Prophylaxis and Treatment in High-Risk Patient Groups.

  2023cites this paper
• VENOUS THROMBOEMBOLISM

  2022influential citation
• Therapeutically dosed low molecular weight heparins in renal impairment: a nationwide survey

  2022cites this paper
• Thrombosis and hemostasis at the University of Padua: a reappraisal on the occasion of its 800th year of history

  2022cites this paper
• Perioperative management of complications

  2022cites this paper
• The Auxiliary Role of Heparin in Bone Regeneration and its Application in Bone Substitute Materials

  2022cites this paper
• How we changed our approach to venous thromboembolism

  2022cites this paper
• Current use of rivaroxaban in elderly patients with venous thromboembolism (VTE)

  2021cites this paper
• Does COVID-19 infection increase the risk of pulmonary embolism in ambulatory patients with deep vein thrombosis

  2021cites this paper
• Anticoagulation for the initial treatment of venous thromboembolism in people with cancer.

  2021cites this paper
• Anticoagulant management by low-dose of low molecular weight heparin in patients with nonvalvular atrial fibrillation following hemorrhagic transformation and complicated with venous thrombosis

  2021cites this paper
• Treatment and Secondary Prevention of Venous Thromboembolic Events in Fragile Patients in a Real-life Practice

  2021cites this paper
• Low-molecular-weight heparin administered by subcutaneous catheter is a safe and effective anti-coagulation regimen in selected inpatient infants and children with complex congenital heart disease

  2021cites this paper
• American Society of Hematology 2021 guidelines for management of venous thromboembolism: prevention and treatment in patients with cancer.

  2021cites this paper
• Cost-effectiveness analysis for the parenteral anticoagulants in Jordan

  2021cites this paper
• Rivaroxaban treatment for young patients with pulmonary embolism (Review)

  2020cites this paper
• In Vitro Study of Synergic Effect of Cisplatin and Low Molecular Weight Heparin on Oral Squamous Cell Carcinoma

  2020cites this paper
• The anti-cancer properties of heparin and its derivatives: a review and prospect

  2020cites this paper
• Massive Fatal Pulmonary Embolism While on Therapeutic Heparin Drip

  2020cites this paper
• Current status of rivaroxaban in elderly patients with pulmonary embolism (Review)

  2020cites this paper
• Clinical Trial Based Rationale for the Successful Use of DOAC in the Treatment of Cerebral Venous Sinus Thrombosis (CVST): A Case Report.

  2020cites this paper
• Review: Inhibitory potential of Low Molecular Weight Heparin in Cell adhesion; Emphasis on Tumor Metastasis.

  2020cites this paper
• Parnaparin in surgery, vascular surgery and associated disciplines

  2020cites this paper
• Pulmonary Embolism

  2020cites this paper
• Heparinoids Danaparoid and Sulodexide as clinically used drugs.

  2019cites this paper
• Comparison of Venous Thromboembolism Prophylactic Measures Post Coronary Artery Bypass Graft Surgery

  2019cites this paper
• Heparin during endovascular stroke treatment seems safe.

  2019cites this paper
• Asymptomatic “breakthrough” thrombosis and anticoagulant “failure”: Keep calm and carry on

  2019cites this paper
• Rivaroxaban does not affect growth of human pancreatic tumors in mice

  2019cites this paper
• Anti-Xa assays: What is their role today in antithrombotic therapy?

  2019cites this paper
• Direct Oral Anticoagulant Drugs: On the Treatment of Cancer-Related Venous Thromboembolism and their Potential Anti-Neoplastic Effect

  2019cites this paper
• The Platelet Lifeline to Cancer: Challenges and Opportunities.

  2018cites this paper
• Pleiotropic effects of heparins: does anticoagulant treatment increase survival in cancer patients?

  2018cites this paper
• Clinical implications of the anatomical variation of deep venous thrombosis

  2018cites this paper
• Anticoagulation for the initial treatment of venous thromboembolism in people with cancer.

  2018cites this paper
• Deep vein thrombosis

  2018cites this paper
• Real-Life Management of Venous Thromboembolism With Rivaroxaban: Results From EXperience VTE, an Italian Epidemiological Survey

  2018cites this paper
• Recurrence of venous thromboembolism among adults acute leukemia patients treated at the University of Texas MD Anderson Cancer Center: Incidence and risk factors.

  2017cites this paper
• THE EFFECT OF APROTININ ON RENAL INJURY IN AN EXPERIMENTAL MODEL OF AORTIC ISCHEMIA-REPERFUSION

  2017cites this paper
• Outpatient Treatment of Deep Vein Thrombosis in the United States: The Reasons for Geographic and Racial Differences in Stroke Study

  2017cites this paper
• Hemostasis and Anticoagulation Therapy

  2017cites this paper
• The Incidence of Recurrent Venous Thromboembolism After Treatment With Vitamin K Antagonists in Relation to Time Since First Event

  2017cites this paper
• Parenteral anticoagulation in ambulatory patients with cancer.

  2017cites this paper
• COMPARISON OF TWICE DAILY LOW-MOLECULAR-WEIGHT HEPARIN VERSUS ONCE DAILY REGIMEN FOR THE TREATMENT OF DEEP VEIN THROMBOSIS

  2017cites this paper
• Update on Perioperative Pulmonary Embolism Management: A Decision Support Tool to Aid in Diagnosis and Treatment.

  2017cites this paper
• Oral anticoagulation in people with cancer who have no therapeutic or prophylactic indication for anticoagulation.

  2017cites this paper
• Fixed dose subcutaneous low molecular weight heparins versus adjusted dose unfractionated heparin for the initial treatment of venous thromboembolism.

  2017cites this paper
• Novel Endothelial Protective and Anti-Thrombotic Effects of Therapeutic Agents in Malignant and Inflammatory Diseases: Molecular Mechanisms and Translational Relevance

  2017cites this paper
• The clinical presentation and natural history of acute deep venous thrombosis

  2017cites this paper
• Non-anticoagulant effects of low molecular weight heparins in inflammatory disorders: A review.

  2017cites this paper
• Association of outcomes and anti‐Xa levels in the treatment of pediatric venous thromboembolism

  2017cites this paper
• Prophylactic anticoagulant therapy decreases the incidence of deep vein thrombosis in patients with solid tumors: A systematic review and meta-analysis

  2017cites this paper
• Therapeutic monitoring of unfractionated heparin – trials and tribulations

  2017cites this paper
• UvA-DARE ( Digital Academic Repository ) Diagnosis , treatment and long-term effects of venous thromboembolism

  2016cites this paper
• Anticoagulants versus cancer.

  2016cites this paper
• Nadroparin in the prophylaxis and treatment of thromboembolic complications in cancer patients

  2016cites this paper
• Anticoagulation Management Practices and Outcomes in Elderly Patients with Acute Venous Thromboembolism: A Clinical Research Study

  2016cites this paper
• Low molecular weight heparin and cancer survival: clinical trials and experimental mechanisms

  2016cites this paper
• Use of heparins in patients with cancer: individual participant data meta-analysis of randomised trials study protocol

  2016cites this paper
• The use of anticoagulants for the treatment and prevention of venous thromboembolism in obese patients: implications for safety

  2016cites this paper
• Pharmacology of Heparin and Related Drugs

  2016influential citation
• Comparing Length of Stay Between Patients Taking Rivaroxaban and Conventional Anticoagulants for Treatment of Venous Thromboembolism

  2016cites this paper
• Unfractionated heparin, low‐molecular‐weight heparin, heparinoid, and pentasaccharide

  2016cites this paper
• The Efficacy of Postoperative Antithrombotics in Free Flap Surgery: A Systematic Review and Meta-Analysis

  2015cites this paper
• Anticoagulant therapy of cancer patients: Will patient selection increase overall survival?

  2015cites this paper
• Heparin in malignant glioma: review of preclinical studies and clinical results

  2015cites this paper
• Predicting recurrences or major bleeding in cancer patients with venous thromboembolism. Findings from the RIETE Registry

  2015cites this paper
• The effect of therapeutic anticoagulation on overall survival in men receiving first-line docetaxel chemotherapy for metastatic castration-resistant prostate cancer.

  2015cites this paper
• Cancer, thrombosis and low-molecular-weight heparins

  2015cites this paper
• Rates of hospitalization among patients with deep vein thrombosis before and after the introduction of rivaroxaban

  2015cites this paper
• Inferior Vena Cava Filters: Placement and Retrieval

  2015cites this paper
• Тромбогеморрагические осложнения в онкохирургии

  2015cites this paper
• Measuring anti-factor xa activity to monitor low-molecular-weight heparin in obesity: a critical review.

  2015cites this paper
• Natural history of venous thromboembolism in patients from the Mediterranean region. A systematic review.

  2014cites this paper
• Secular trends in occurrence of acute venous thromboembolism: the Worcester VTE study (1985-2009).

  2014cites this paper
• Management of venous thromboembolism in cancer patients

  2014cites this paper
• Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines

  2014cites this paper
• Anticoagulation for the initial treatment of venous thromboembolism in patients with cancer.

  2014cites this paper
• Treatment of deep vein thrombosis

  2014cites this paper
• Clinical and safety outcomes associated with treatment of acute venous thromboembolism: a systematic review and meta-analysis.

  2014cites this paper
• Advantages and limitations of the new anticoagulants

  2014cites this paper
• A Population-Based Perspective onClinically Recognized Venous Thromboembolism:Contemporary Trends in Clinical Epidemiology andRisk Assessment of Recurrent Events: A Dissertation

  2014cites this paper
• Historia natural de la enfermedad tromboembólica venosa en el área mediterránea. Una revisión sistemática

  2014cites this paper
• UvA-DARE ( Digital Academic Repository ) Epidemiology , diagnosis and treatment of cerebral venous thrombosis

  2014cites this paper
• Low-molecular weight heparin in the treatment of patients with venous

  2014cites this paper
• Length of stay and economic consequences with rivaroxaban vs enoxaparin/vitamin K antagonist in patients with DVT and PE: findings from the North American EINSTEIN clinical trial program

  2014cites this paper
• Parenteral anticoagulation in ambulatory patients with cancer.

  2014cites this paper
• Considerations, Monitoring, Efficacy, andSafety

  2013cites this paper
• Treatment for Patients With Cancer

  2013cites this paper
• Anticoagulant Treatment in Patients with Cancer and Venous Thrombosis Recurrent Venous Thromboembolism and Bleeding Complications During

  2013cites this paper
• Once versus twice daily low molecular weight heparin for the initial treatment of venous thromboembolism.

  2013cites this paper